Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | April 07, 2025 | April 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date April 07, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 312,995 |
Reported balance
After 2025-04-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-04-07 · Exercise / conversion · Acquired 24,000 · Balance 312,995 F1: Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025. F2: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2025-12-01 | Direct | 0 |
Reported balance
After 2025-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-07 · Exercise / conversion · Disposed 24,000 · Balance 0 F1: Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025. F3: This option has fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025.
F2: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time.
F3: This option has fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2025 Filed Apr 8, 2025 20:41 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | Exercise / conversionStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001760016-25-000004 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Shares · 24,000 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025. F3 · derivative.exercise_date: This option has fully vested. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 20:41 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | Exercise / conversionVoting Common Shares, no par value per share | 24,000 | $2.11 | $50,640.00 |
DisclosureSEC source: 0001760016-25-000004 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:23 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 10,393 | $5.34 | $55,498.62 |
DisclosureSEC source: 0001235802-25-000002 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,995 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $55,500. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:29 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 36,065 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000048 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,065 Underlying: Common Shares · 36,065 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:47 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 30,357 | $2.80 | $84,999.60 |
DisclosureSEC source: 0001235802-24-000003 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,602 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 129,561 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:03 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 38,363 | $3.91 | $149,999.33 |
DisclosureSEC source: 0001235802-23-000068 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,245 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 99,204 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:26 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 22,355 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000059 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,355 Underlying: Common Shares · 22,355 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 21:19 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 55,555 | $1.53 | $84,999.15 |
DisclosureSEC source: 0001235802-23-000001 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,882 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 99,204 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 21:16 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 35,000 | $1.39 | $48,492.50 |
DisclosureSEC source: 0001235802-22-000130 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,327 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3665 to $1.4047, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 43,649 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:38 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 18,510 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000071 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,510 Underlying: Common Shares · 18,510 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:26 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 23,762 | $3.58 | $85,067.96 |
DisclosureSEC source: 0001235802-22-000003 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,327 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 43,649 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:05 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 12,500 | $3.28 | $41,032.50 |
DisclosureSEC source: 0001235802-21-000100 · primary_doc.xml · nonDerivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,565 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 19,887 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:05 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 2,500 | $3.21 | $8,031.50 |
DisclosureSEC source: 0001235802-21-000100 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,065 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 19,887 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:40 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 13,150 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000080 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,150 Underlying: Common Shares · 13,150 shares Expires 2031-07-14 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 21:12 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 9,719 | $8.23 | $79,987.37 |
DisclosureSEC source: 0001235802-21-000001 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,565 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $80,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 19,887 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 22:46 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 5,000 | $5.24 | $26,200.00 |
DisclosureSEC source: 0001790300-20-000011 · primary_doc.xml · nonDerivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,846 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 10,168 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 22:46 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 5,000 | $5.50 | $27,497.00 |
DisclosureSEC source: 0001790300-20-000011 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,846 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 10,168 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:33 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 19,220 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000049 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,220 Underlying: Common Shares · 19,220 shares Expires 2030-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:33 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 10,168 | $4.59 | $46,671.12 |
DisclosureSEC source: 0001235802-20-000049 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,846 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $46,667. F2 · balance_after: Includes 7,588 shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 10:45 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 7,840 | $2.56 | $20,039.04 |
DisclosureSEC source: 0001235802-19-000107 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,678 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.5387 to $2.5775, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:48 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 18,700 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000065 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Shares · 18,700 shares Expires 2029-06-23 F2 · derivative.exercise_date: Vests in four equal quarterly installments over one year. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:11 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 19,000 | $2.80 | $53,200.00 |
DisclosureSEC source: 0001235802-19-000045 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.74 to $2.80, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:37 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 6,250 | $4.00 | $25,000.00 |
DisclosureSEC source: 0001235802-18-000183 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,838 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.